TNFSF10 and breast carcinoma: 324,325 Taking advantage of these interactions, Hu and colleagues developed a platelet membrane-coated nanovehicle decorated with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and loaded with doxorubicin (designated TRAIL-Dox-PM-NV) to kill primary tumor cells, as well as to eliminate CTCs.326 After intravenous administration, TRAIL-Dox-PM-NV selectively accumulated at tumor sites and significantly inhibited the growth of primary tumors in a xenograft mouse model of breast cancer.